European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action


Por: Luedde, M, Agewall, S, Ambrosio, G, Bayes-Genis, A, Borghi, C, Cerbai, E, Dan, GA, Drexel, H, Ferdinandy, P, Grove, EL, Kaski, JC, Klingenberg, R, Morais, J, Parker, W, Petrie, MC, Rocca, B, Semb, AG, Senni, M, Sohns, C, Sulzgruber, P, Tamargo, J, Metra, M, Böhm, M, Dobrev, D and Sossalla, S

Publicada: 1 nov 2025 Ahead of Print: 1 oct 2025
Resumen:
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non-adherence and side effects. While rhythm control strategies in AF have gained attention for their prognostic benefits in HF, the pharmacological treatment of HF in patients with AF, including the benefit of rhythm versus rate control, remains underexplored. The relationship between HF and AF lacks sufficient evidence and targeted research to assess the optimal treatment strategies. This narrative review critically examines current HF pharmacotherapy in the context of AF, focusing on the four cornerstone treatments and modifiers of prognosis for HF with reduced ejection fraction: beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/sacubitril-valsartan, aldosterone antagonists, and sodium-glucose co-transporter 2 inhibitors. Although these therapies are well-established in HF patients, their efficacy in patients with concomitant AF requires further prospective investigation. The unique challenges posed by AF, including arrhythmia-induced remodelling and cardiomyopathy, necessitate a more individually tailored treatment. We also highlight critical knowledge gaps and the need for dedicated clinical trials specifically assessing HF therapies in AF subgroups, such as paroxysmal, long-standing persistent and permanent AF, and the benefit of heart rate and rhythm control strategies. The future of precision medicine in HF-AF management lies in bridging these evidence gaps through targeted research and interdisciplinary collaboration.

Filiaciones:
Luedde, M:
 Justus Liebig Univ Giessen, Med Clin 1, Cardiol & Angiol, Klin Str 33, D-35392 Giessen, Germany

 Sanecum Grp, Cardiologicum Bremerhaven, Bremerhaven, Germany

Agewall, S:
 Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden

Ambrosio, G:
 Univ Perugia, Sch Med, Dept Med, Perugia, Italy

 Univ Perugia, Sch Med, CERICLET, Perugia, Italy

 Inst Cardiovasc Res INRC, Perugia, Italy

:
 Hosp Univ Germans Trias i Pujol, Heart Inst, CIBERCV, Badalona, Spain

Borghi, C:
 Univ Bologna, Dept Cardiovasc Med, IRCCS AOU S Orsola, Bologna, Italy

Cerbai, E:
 Univ Florence, Dept Neurosci, Sect Pharmacol & Toxicol, Florence, Italy

Dan, GA:
 Carol Davila Univ Med & Pharm, Acad Romanian Scientists, Bucharest, Romania

Drexel, H:
 Vorarlberg Inst Vasc Invest & Treatment VIVIT, Feldkirch, Austria

Ferdinandy, P:
 Pharmahungary Grp, Szeged, Hungary

 Semmelweis Univ, Ctr Pharmacol & Drug Res & Dev, Budapest, Hungary

Grove, EL:
 Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark

 Aarhus Univ, Fac Hlth, Dept Clin Med, Aarhus, Denmark

Kaski, JC:
 St Georges Univ London, Cardiovasc & Cell Sci Res Inst, London, England

Klingenberg, R:
 Justus Liebig Univ Giessen, Med Clin 1, Cardiol & Angiol, Klin Str 33, D-35392 Giessen, Germany

 Kerckhoff Clin DZHK, Dept Cardiol, Bad Nauheim, Germany

 Stiftung Hosp zum Heiligen Geist, Krankenhaus Nordwest, Frankfurt, Germany

Morais, J:
 Polytech Univ Leiria, CiTechCare Ctr Innovat Care & Hlth Technol, Leiria, Portugal

Parker, W:
 Univ Sheffield, Cardiovasc Res Unit, Sheffield, England

Petrie, MC:
 Univ Glasgow, Sch Cardiovasc & Med Sci, Glasgow, Scotland

Rocca, B:
 LUM Univ, Dept Med & Surg, Casamassima, Italy

Semb, AG:
 Diakonhjemmet Hosp, REMEDY Ctr, Div Res & Innovat, Prevent Cardiorheuma Clin, Oslo, Norway

Senni, M:
 Univ Milano Bicocca, Papa Giovanni XXIII Hosp, Cardiovasc Dept, Bergamo, Italy

Sohns, C:
 Ruhr Univ Bochum, Dept Electrophysiol Herz & Diabet Zentrum NRW, Bad Oeynhausen, Germany

Sulzgruber, P:
 Med Univ Vienna, Dept Med, Div Cardiol, Vienna, Austria

Tamargo, J:
 Univ Complutense, Sch Med, Dept Pharmacol & Toxicol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

Metra, M:
 Univ Brescia, Cardiol, Dept Med & Surg Specialties Radiol Sci & Publ Hlth, ASST Spedali Civili, Brescia, Italy

Böhm, M:
 Saarland Univ, Univ Klinikum Saarlandes, HOMICAREM HOMburg Inst CArdioREnalMetabol Med, Klin Innere Med 3, Homburg Saar, Germany

Dobrev, D:
 Univ Duisburg Essen, Inst Pharmacol, West German Heart & Vasc Ctr, Essen, Germany

 Montreal Heart Inst, Dept Med, Montreal, PQ, Canada

 Univ Montreal, Montreal, PQ, Canada

 Baylor Coll Med, Dept Integrat Physiol, Houston, TX USA

Sossalla, S:
 Justus Liebig Univ Giessen, Med Clin 1, Cardiol & Angiol, Klin Str 33, D-35392 Giessen, Germany

 Kerckhoff Clin DZHK, Dept Cardiol, Bad Nauheim, Germany

 Excellence Cluster Cardiopulm Insitute CPI, Klin Str 33, Giessen, Germany
ISSN: 13889842





European Journal of Heart Failure
Editorial
Wiley-Blackwell, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Review
Volumen: 27 Número: 11
Páginas: 2198-2210
WOS Id: 001597476000001
ID de PubMed: 41123042
imagen Green Accepted, Green Submitted, hybrid

MÉTRICAS